Drug_Name,STUDYID,YEAR,Country,Dataset,Patient_Count,Median_Age,Female_Percentage,Male_Percentage,Median_BMI,Smoking_History_Yes_Percentage,Total_ADL_Independence_Percentage,LHRH_Use_Percentage,Tumor_Stage_T1_Percentage,Tumor_Stage_T2_Percentage,Tumor_Stage_T3_Percentage,Tumor_Stage_T4_Percentage,Nodal_Stage_N0_Percentage,Nodal_Stage_N1_Percentage,Nodal_Stage_N2_Percentage,Nodal_Stage_N3_Percentage,Stage_I_Percentage,Stage_II_Percentage,Stage_III_Percentage,Diabetes_Mellitus_Percentage,Congestive_Heart_Failure_Percentage,Stroke_Percentage,Atrial_Fibrillation_Percentage,Myocardial_Infarction_Percentage,Neoadjuvant_Chemotherapy_Received_Percentage,Adjuvant_Chemotherapy_Received_Percentage,Postoperative_RT_Received_Percentage,Common_Neoadjuvant_Regimen_1,Common_Neoadjuvant_Regimen_2,Common_Adjuvant_Regimen_1,Common_Adjuvant_Regimen_2,Tamoxifen_Percentage,Letrozole_Percentage,Anastrozole_Percentage,Antidiarrheal_Agent_Probiotics_Percentage,Antiemetic_Agent_Percentage,Painkiller_Antipyretic_Percentage,Beds_Less_Than_200_Percentage,Beds_200_To_499_Percentage,Beds_Greater_Or_Equal_To_500_Percentage,Designated_Cancer_Hospital_Percentage,Months_Between_Surgery_And_Index_Date
Everolimus,EVE1001,2021,USA,MDV,350,68,35,65,27.5,42,85,15,18,32,25,25,45,30,15,10,20,35,45,18,8,5,12,7,5,10,22,None,None,AC,CMF,25,15,10,30,40,50,15,45,40,60,2
Everolimus,EVE1002,2022,Canada,Claim Database,420,72,40,60,28.1,38,78,18,20,30,28,22,40,35,17,8,18,32,50,20,10,6,14,9,7,12,25,None,None,AC-T,CMF,28,17,12,35,45,55,12,48,40,65,3
Everolimus,EVE1003,2023,UK,MDV,280,65,30,70,26.8,45,90,20,22,35,20,23,50,25,13,12,22,38,40,15,7,4,11,6,6,11,20,None,None,FEC,Taxol,22,13,8,28,38,48,18,42,40,55,2.5
Everolimus,EVE1004,2023,Germany,Claim Database,480,70,38,62,27.9,40,80,17,19,33,26,22,43,32,16,9,19,33,48,19,9,5,13,8,8,13,24,None,None,EC,Docetaxel,27,16,11,33,43,53,14,46,40,62,3.2
